TWI704917B - 治療嚴重便祕的組合物及方法 - Google Patents

治療嚴重便祕的組合物及方法 Download PDF

Info

Publication number
TWI704917B
TWI704917B TW108109164A TW108109164A TWI704917B TW I704917 B TWI704917 B TW I704917B TW 108109164 A TW108109164 A TW 108109164A TW 108109164 A TW108109164 A TW 108109164A TW I704917 B TWI704917 B TW I704917B
Authority
TW
Taiwan
Prior art keywords
dgat1
inhibitor
constipation
individual
pharmaceutically acceptable
Prior art date
Application number
TW108109164A
Other languages
English (en)
Chinese (zh)
Other versions
TW201944995A (zh
Inventor
布萊恩 Ｋ 哈伯德
吳 麥可 Ｈ 瑟藍諾
Original Assignee
開曼群島商安濟藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商安濟藥業有限公司 filed Critical 開曼群島商安濟藥業有限公司
Publication of TW201944995A publication Critical patent/TW201944995A/zh
Application granted granted Critical
Publication of TWI704917B publication Critical patent/TWI704917B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108109164A 2018-03-16 2019-03-18 治療嚴重便祕的組合物及方法 TWI704917B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16

Publications (2)

Publication Number Publication Date
TW201944995A TW201944995A (zh) 2019-12-01
TWI704917B true TWI704917B (zh) 2020-09-21

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108109164A TWI704917B (zh) 2018-03-16 2019-03-18 治療嚴重便祕的組合物及方法

Country Status (17)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
JP2004502686A (ja) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
KR100772297B1 (ko) 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
EP1718309A2 (en) 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008516978A (ja) 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
KR20080000652A (ko) 2005-04-19 2008-01-02 바이엘 파마슈티칼스 코포레이션 아릴 알킬산 유도체 및 그의 용도
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
MA34097B1 (fr) * 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
WO2011126967A1 (en) * 2010-04-08 2011-10-13 Medicinova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Denison, C. Nilsson, M. Kujacic, L. Löfgren, C. Karlsson, M. Knutsson, J. W. Eriksson, "Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single-dose study"Diabetes Obesity and Metabolism 15(2) , September 2012. *
Kenneth Kulmatycki et al.,"Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor", International Journal of Clinical Pharmacology and Therapeutics, Vol. 53,No. 5, 2015, page 345-355. *

Also Published As

Publication number Publication date
KR102747096B1 (ko) 2024-12-26
IL277332B1 (en) 2024-09-01
US20260000651A1 (en) 2026-01-01
CA3093970A1 (en) 2019-09-19
AU2019234956B2 (en) 2025-01-30
US11819495B2 (en) 2023-11-21
EP3765012B1 (en) 2026-03-04
MY205335A (en) 2024-10-16
JP2021518431A (ja) 2021-08-02
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
PH12020551468A1 (en) 2021-09-01
BR112020018790A2 (pt) 2020-10-13
AU2019234956A1 (en) 2020-10-01
EP3765012A4 (en) 2021-12-15
IL277332A (en) 2020-10-29
IL277332B2 (en) 2025-01-01
US20220193044A1 (en) 2022-06-23
CN111936137A (zh) 2020-11-13
KR20200136428A (ko) 2020-12-07
EP3765012A1 (en) 2021-01-20
JP7527984B2 (ja) 2024-08-05
EA202092190A1 (ru) 2020-11-19
PE20210158A1 (es) 2021-01-26
TW201944995A (zh) 2019-12-01
MX2020009604A (es) 2023-01-25
US11224590B2 (en) 2022-01-18
US20190282549A1 (en) 2019-09-19
SG11202008971VA (en) 2020-10-29
US12343334B2 (en) 2025-07-01
CN111936137B (zh) 2023-09-08
FI3765012T3 (fi) 2026-04-17

Similar Documents

Publication Publication Date Title
JP7835558B2 (ja) 動物における疼痛の処置のためのアサ抽出物
US20260000651A1 (en) Compositions and methods for treating severe constipation
US20100160351A1 (en) Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2685992A1 (en) Amino-quinolines as kinase inhibitors
CN105769928B (zh) 丁酸梭状芽孢杆菌在防治或辅助治疗高血糖制剂中的应用
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
CN117771238B (zh) 苯丙酸类似物在治疗或预防代谢紊乱中的用途
US9132108B2 (en) Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
CA3191276A1 (en) Ionic liquid formulations for treating diabetes
KR20150063006A (ko) 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물
CA3093970C (en) Compositions and methods for treating severe constipation
JP2019522030A (ja) 肝性脳症の治療方法
WO2025011534A1 (zh) 用于增强运动表现的方法及组合物
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
CA3051789A1 (fr) Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal
KR20130035425A (ko) Ｈｓ1792를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
TWI609689B (zh) 改善腎臟病患者之腎臟功能和/或心臟功能的方法
EA030590B1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника
AU2012229871B2 (en) New composition
CN120168490A (zh) 化合物及其组合物在制备治疗非酒精性脂肪肝的药物中的应用
JP2025154328A (ja) 腎障害の予防用または治療用組成物
CN111050775A (zh) 提高氨基葡萄糖类的生物利用度的方法
JP2006206547A (ja) 頻尿改善剤およびそれを含む医薬組成物および食品